NCT06092047 2025-05-16
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
1 trialsPhase EARLY_PHASE1 × INDUSTRY × CD19-positive Relapsed or Refractory B-cell Malignancies × Clear all